The Business Case For Post-Grant Patent Review
Executive Summary
Counsels’ view of what inter parte reviews and other new procedures introduced by the America Invents Act mean to the biopharma industry.
You may also be interested in...
The Patent Trolls Are Coming...To Medtech
For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.
Patent Trolls Eye Biotech Firms; New PTO Proceedings Are ‘Game Changer’
Patent review proceedings established by America Invents Act may become ‘close second’ to ANDA litigation as way to invalidate patents; industry calls for changes as patent claims are routinely struck down.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”